Alnylam Pharmaceuticals, Inc.
A biopharmaceutical company that makes RNAi therapeutics — medicines that "silence" disease-causing genes — with six marketed drugs including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare conditions like ATTR amyloidosis. Founded in 2002 by Nobel laureate Phillip Sharp and fellow scientists, its name comes from Alnilam, the bright center star of Orion's belt, chosen as an "aspirational North Star" for genomic medicine. Its ONPATTRO was the first RNAi drug ever approved by the FDA, in 2018.
Granted 101.4K · Sold 60.8K
Granted 25.2K · Sold 13.5K
Granted 17.1K · Sold 12.3K
Granted 4.5K · Sold 3.8K
Granted 12.1K
Granted 21.0K · Sold 22.5K
Granted 24.8K · Sold 26.9K
Granted 14.6K
Sold 3.9K
Granted 671
Granted 671
Granted 671
Granted 18.7K · Sold 18.0K
Granted 671
Granted 671
Granted 671
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Greenstreet YvonneChief Executive Officer, Director · 86 transactions | +57.4% | 98.8K | 101.4K | — | 60.8K |
| Poulton Jeffrey V.EVP, Chief Financial Officer · 58 transactions | +25.9% | 63.2K | 25.2K | — | 13.5K |
| Tanguler TolgaEVP, Chief Commercial Officer · 63 transactions | +16.4% | 34.3K | 17.1K | — | 12.3K |
| Pyott David E IDirector · 7 transactions | +4.1% | 30.0K | 4.5K | — | 3.8K |
| Schulman Amy WDirector · 2 transactions | +101.1% | 24.0K | 12.1K | — | — |
| Garg PushkalEVP Chief R&D · 76 transactions | -4.3% | 21.1K | 21.0K | — | 22.5K |
| Fitzgerald Kevin JosephCSO & EVP, Head of Research · 85 transactions | -10.2% | 21.1K | 24.8K | — | 26.9K |
| Supran BryanEVP, CLO and Secretary · 2 transactions | — | 14.6K | 14.6K | — | — |
| McLaughlin MelissaChief Human Resources Officer · 14 transactions | — | 13.4K | — | — | 3.9K |
| Ausiello Dennis ADirector · 1 transaction | +0.6% | 5.1K | 671 | — | — |
| Sigal Charles ElliottDirector · 1 transaction | +24.2% | 3.4K | 671 | — | — |
| Hamburg Margaret ADirector · 1 transaction | +73.7% | 1.6K | 671 | — | — |
| Reitan Colleen FDirector · 18 transactions | +86.6% | 1.4K | 18.7K | — | 18.0K |
| Brandicourt OlivierDirector · 1 transaction | +86.6% | 1.4K | 671 | — | — |
| Kellogg Peter NDirector · 1 transaction | +86.6% | 1.4K | 671 | — | — |
| Arbuckle Stuart ADirector · 1 transaction | — | 671 | 671 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -161.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.